Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
dc.contributor.author | Valle, Juan W | |
dc.contributor.author | Borbath, I | |
dc.contributor.author | Rosbrook, B | |
dc.contributor.author | Fernandez, K | |
dc.contributor.author | Raymond, E | |
dc.date.accessioned | 2019-03-04T12:32:42Z | |
dc.date.available | 2019-03-04T12:32:42Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Valle JW, Borbath I, Rosbrook B, Fernandez K, Raymond E. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncol. 2019 Jan 31. | en |
dc.identifier.pmid | 30701988 | en |
dc.identifier.doi | 10.2217/fon-2018-0882 | en |
dc.identifier.uri | http://hdl.handle.net/10541/621557 | |
dc.description.abstract | AIM: To describe the long-term safety of sunitinib in patients with progressive, well-differentiated, advanced/metastatic pancreatic neuroendocrine tumors. PATIENTS & METHODS: Sunitinib- and placebo-treated patients from the Phase III study continued to receive sunitinib (37.5 mg on a continuous daily-dosing regimen) in two open-label extension studies. RESULTS: Median (range) treatment exposure: 30.2 (0.7-269.4) and 87.1 (3.9-319.4) weeks for medium-term (n = 41) and long-term-treated (n = 61) populations, respectively. All patients experienced ?1 adverse event (AE); 47 (45.6%) reported serious AEs. Common all-causality AEs: diarrhea (63.1%); neutropenia (43.7%); abdominal pain (40.8%). Fifteen (14.6%) patients discontinued treatment due to treatment-related AEs. CONCLUSION: The safety of extended sunitinib treatment was consistent with the known safety profile of sunitinib in pancreatic neuroendocrine tumors | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.2217/fon-2018-0882 | en |
dc.title | Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. | en |
dc.type | Article | en |
dc.contributor.department | Division of Cancer Sciences/Department of Medical Oncology, The Christie NHS Foundation Trust, University of Manchester, Manchester M20 4BX, UK | en |
dc.identifier.journal | Future Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2019-03-07T17:32:30Z |